While Ideaya Biosciences Inc has underperformed by -0.63%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IDYA rose by 199.15%, with highs and lows ranging from $47.74 to $13.29, whereas the simple moving average jumped by 29.41% in the last 200 days.
On March 08, 2024, BTIG Research started tracking Ideaya Biosciences Inc (NASDAQ: IDYA) recommending Buy. A report published by SVB Securities on August 08, 2023, Initiated its previous ‘Outperform’ rating for IDYA. Goldman also rated IDYA shares as ‘Buy’, setting a target price of $32 on the company’s shares in an initiating report dated May 24, 2023. Stifel April 24, 2023d the rating to Buy on April 24, 2023, and set its price target from $18 to $24. Berenberg initiated its ‘Buy’ rating for IDYA, as published in its report on March 23, 2023. RBC Capital Mkts’s report from February 28, 2023 suggests a price prediction of $25 for IDYA shares, giving the stock a ‘Outperform’ rating. CapitalOne also rated the stock as ‘Overweight’.
Analysis of Ideaya Biosciences Inc (IDYA)
Further, the quarter-over-quarter decrease in sales is -2.46%, showing a negative trend in the upcoming months.
One of the most important indicators of Ideaya Biosciences Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -23.28% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 19.65, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and IDYA is recording 913.19K average volume. On a monthly basis, the volatility of the stock is set at 3.88%, whereas on a weekly basis, it is put at 3.74%, with a gain of 0.36% over the past seven days. Furthermore, long-term investors anticipate a median target price of $53.27, showing growth from the present price of $42.30, which can serve as yet another indication of whether IDYA is worth investing in or should be passed over.
How Do You Analyze Ideaya Biosciences Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.68%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 80.96% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
IDYA shares are owned by institutional investors to the tune of 80.96% at present.
